Latest Insider Transactions at Editas Medicine, Inc. (EDIT)
This section provides a real-time view of insider transactions for Editas Medicine, Inc. (EDIT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Editas Medicine, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Editas Medicine, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 07
2020
|
Charles Albright EVP/Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
20,000
-44.54%
|
$800,000
$40.02 P/Share
|
|
Dec 07
2020
|
Charles Albright EVP/Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+30.81%
|
$320,000
$16.51 P/Share
|
|
Nov 09
2020
|
Charles Albright EVP/Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
228
-0.91%
|
$7,068
$31.21 P/Share
|
|
Nov 09
2020
|
Lisa Anne Michaels EVP/Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
-
|
|
Oct 15
2020
|
Charles Albright EVP/Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,000
-10.66%
|
$93,000
$31.39 P/Share
|
|
Feb 08
2015
|
Viking Global Investors LP > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,020,407
+40.39%
|
-
|
|
Feb 08
2015
|
Viking Global Investors LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,709,401
+50.0%
|
-
|
|
Feb 08
2015
|
Viking Global Investors LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,020,407
+13.85%
|
-
|
|
Feb 08
2015
|
Viking Global Investors LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,709,401
+50.0%
|
-
|